Reverse Merger - Summary of Pro Forma Results of Operation (Detail) - OncoGenex Pharmaceuticals, Inc [Member] - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
| Business Acquisition [Line Items] | ||||
| Revenue | $ 5,062 | |||
| Net loss applicable to common shareholders | $ (9,730) | $ (4,197) | $ (10,100) | $ (15,034) |
| Net loss per share-basic and diluted | $ (1.35) | $ (0.14) | $ (4.15) | $ (0.50) |
| Weighted average shares | 7,225,826 | 30,013,928 | 2,435,095 | 29,925,479 |
| X | ||||||||||
- Definition Business acquisition pro forma earnings per share basic and diluted. No definition available.
|
| X | ||||||||||
- Definition Business acquisition pro forma weighted average shares. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|